813 related articles for article (PubMed ID: 15996702)
1. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
2. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
3. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Johansson BE
Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
5. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
[TBL] [Abstract][Full Text] [Related]
6. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
7. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR
J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536
[TBL] [Abstract][Full Text] [Related]
8. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
Johansson BE; Matthews JT; Kilbourne ED
Vaccine; 1998; 16(9-10):1009-15. PubMed ID: 9682352
[TBL] [Abstract][Full Text] [Related]
9. Changing perspective on immunization against influenza.
Johansson BE; Brett IC
Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
[TBL] [Abstract][Full Text] [Related]
10. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
[TBL] [Abstract][Full Text] [Related]
11. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Johansson BE; Kilbourne ED
Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
[TBL] [Abstract][Full Text] [Related]
12. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2).
Tang M; Harp JA; Wesley RD
Arch Virol; 2002 Nov; 147(11):2125-41. PubMed ID: 12417948
[TBL] [Abstract][Full Text] [Related]
13. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Johansson BE; Pokorny BA; Tiso VA
Vaccine; 2002 Feb; 20(11-12):1670-4. PubMed ID: 11858877
[TBL] [Abstract][Full Text] [Related]
14. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
15. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
[TBL] [Abstract][Full Text] [Related]
16. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
17. Protection of mice with recombinant influenza virus neuraminidase.
Kilbourne ED; Pokorny BA; Johansson B; Brett I; Milev Y; Matthews JT
J Infect Dis; 2004 Feb; 189(3):459-61. PubMed ID: 14745703
[TBL] [Abstract][Full Text] [Related]
18. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
19. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
20. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines.
Johansson BE; Brett IC
Hum Vaccin; 2008; 4(6):420-4. PubMed ID: 18535408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]